It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alcoholic hepatitis (AH) is associated with liver neutrophil infiltration through activated cytokine pathways leading to elevated chemokine expression. Super-enhancers are expansive regulatory elements driving augmented gene expression. Here, we explore the mechanistic role of super-enhancers linking cytokine TNFα with chemokine amplification in AH. RNA-seq and histone modification ChIP-seq of human liver explants show upregulation of multiple CXCL chemokines in AH. Liver sinusoidal endothelial cells (LSEC) are identified as an important source of CXCL expression in human liver, regulated by TNFα/NF-κB signaling. A super-enhancer is identified for multiple CXCL genes by multiple approaches. dCas9-KRAB-mediated epigenome editing or pharmacologic inhibition of Bromodomain and Extraterminal (BET) proteins, transcriptional regulators vital to super-enhancer function, decreases chemokine expression in vitro and decreases neutrophil infiltration in murine models of AH. Our findings highlight the role of super-enhancer in propagating inflammatory signaling by inducing chemokine expression and the therapeutic potential of BET inhibition in AH treatment.
Alcoholic hepatitis is characterized by intense liver inflammation driven by excessive cytokines and chemokines production and immune cell infiltration. Here the authors identify a super-enhancer that regulates the expression of multiple CXCL chemokines in alcoholic hepatitis and may be a potential therapeutic target.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
2 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Department of Gastroenterology, Wuhan, China (GRID:grid.412793.a) (ISNI:0000 0004 1799 5032)
3 West China Hospital, Sichuan University, Lab of Gastroenterology and Hepatology, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022)
4 School of Medicine of the Pontificia Universidad Católica de Chile, Department of Gastroenterology and Hepatology, Santiago, Chile (GRID:grid.7870.8) (ISNI:0000 0001 2157 0406)
5 University of Minnesota, Department of Chemistry, Minneapolis, USA (GRID:grid.17635.36) (ISNI:0000000419368657)
6 Henan Provincial People’s Hospital, Department of Respiratory and Critical Care Medicine, Zhengzhou, China (GRID:grid.414011.1) (ISNI:0000 0004 1808 090X); Mayo Clinic, Department of Pulmonary and Critical Care Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
7 Mayo Clinic, Department of Physiology and Biomedical Engineering, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
8 University of Pittsburgh, Department of Gastroenterology Hepatology and Nutrition, Pittsburgh, USA (GRID:grid.21925.3d) (ISNI:0000 0004 1936 9000)
9 Mayo Clinic, Center for Individualized Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
10 Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic, Department of Physiology and Biomedical Engineering, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic, Center for Individualized Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
11 University of Lille, Lille, France (GRID:grid.503422.2) (ISNI:0000 0001 2242 6780)